filgrastim Archives

Amneal launches Releuko® (biosimilar filgrastim) in the US

by Bioblast Editor | Nov 22, 2022 | Biosimilars updates

Amneal announced the launch of Releuko® (biosimilar filgrastim) for the treatment of neutropenia. Amneal and Amgen settled their patent dispute in November 2019. This is the second biosimilar product to be launched by Amneal this year, following the US launch of...

FDA approves Amneal’s Releuko™ (biosimilar filgrastim)

by Bioblast Editor | Mar 1, 2022 | Biosimilars updates

Amneal announced that the FDA has approved Amneal’s first biosimilar product Releuko™ (biosimilar filgrastim), a product developed by Kashiv Speciality Pharmaceuticals (which was acquired by Amneal in April 2021). Amneal also disclosed that US applications for...

Amneal to acquire Saol’s Baclofen franchise

by Bioblast Editor | Jan 5, 2022 | Biosimilars updates

Amneal Pharmaceuticals and Saol Therapeutics announced that Amneal will acquire Saol’s Baclofen franchise. This acquisition is expected to bolster Amneal’s commercial infrastructure in advance of its planned launches of biosimilar filgrastim,...

Amgen and Hospira ready to settle Neupogen® (filgrastim) dispute

by Bioblast Editor | Sep 2, 2021 | Biosimilars updates

Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The matter was due to go to a jury trial on 20 September 2021.

Study approves of Sandoz’s Zarxio® as treatment of cancer

by Bioblast Editor | Oct 6, 2020 | Biosimilars updates

Onco’Zine reports a new study released by the American Society of Clinical Oncology Quality Care Symposium indicates that Sandoz’s Zarxio® (biosimilar filgrastim) is not only safe and effective, but is cost effective in treating chemotherapy-induced...